Status:
UNKNOWN
the Change of CEM and the Prognosis of Coronary Artery Disease in Real Clinical Practice
Lead Sponsor:
Lu'an Municipal Hospital
Collaborating Sponsors:
First Affiliated Hospital of Jinan University
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
45-70 years
Brief Summary
The purpose of this study is to investigate the change of total cholesterol content of erythrocyte membranes (CEM) in patients with coronary artery disease treated with secondary prevention drugs, and...
Detailed Description
In this clinical trial, plasma samples, the red cells and associated clinical data of patients with coronary artery disease were collected from Department of Cardiology of Lu'an Shili Hospital and the...
Eligibility Criteria
Inclusion
- Signed informed consent;
- First diagnosis of CAD through CAG;
- Aged 45-70.
Exclusion
- Patients with severe liver or kidney damage;
- Taking statins within the last 3 months;
- Patients who had been diagnosed with CAD and treated with oral medication;
- Chronic diseases of the blood system;
- Familial hyperlipidemia patients;
- Patients combining autoimmune disease;
- Patients combining acute infectious disease;
- Patients who undertaken surgery or injury;
- Patients who combining cancer;
- Patients who taking glucocorticoid replacement therapy;
- Abnormal red blood cell (RBC) count (M: \<4.0 or \>5.5 × 1012/L; F: \<3.5 or \>5.0 × 1012/L) or abnormal hemoglobin (M: \<120 or \>160 g/L; F: \<110 or \>150 g/L).
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03473860
Start Date
April 1 2018
End Date
December 31 2021
Last Update
March 22 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.